Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2007

View Archived Issues

Phase I and II studies of belinostat presented at AACR-NCI-EORTC congress

Weight loss synergy seen with bupropion/naltrexone in obesity study

Intratumoral TNFerade injection feasible in rectal cancer patients

Preclinical studies support investigation of AT-101 in lung cancer

Novel treatment options for bacterial infections claimed in recent patents

Novel therapeutic agents for genetic disorders reported in recent Technion patent

Recent patents describe novel antidiabetic agents

Repligen reports positive phase IIa clinical trial results for RG-2417

BioGeneriX and Neose report positive data from two phase I trials of GlycoPEG-GCSF

Teva and Active Biotech initiate enrollment in phase III Allegro clinical trial of laquinimod

Synta initiates phase I clinical study of novel Hsp90 inhibitor STA-9090

Dynogen initiates phase IIb of DDP-733 for irritable bowel syndrome with constipation

Biopure responds to U.K. commission on human medicines' review of Hemopure

AVEO reports positive results from phase I clinical trial of AV-951

Novel chronic pain therapy not associated with the development of tolerance

Selective ERbeta activation using WAY-200070 effective in models of anxiety and depression

Elan designs gamma-secretase inhibitors with selectivity over Notch

Results from preclinical, clinical studies support potential of adipiplon as treatment for insomnia

Peptech renamed Arana Therapeutics and announces new strategic business plan

Epiphany initiates phase IIb clinical trial of valomaciclovir for the treatment of shingles

Sanofi pasteur initiates phase II study of cell culture-based seasonal influenza vaccine

Improved BACE1 inhibitor at Merck & Co.

AlphaRx reports positive preclinical data from clinical trial of Vansolin

LifeCycle Pharma reports positive results from clinical trial of LCP-Tacro

Study shows fewer and smaller dose adjustments necessary in treatment with Transtec

Cephalon submits supplemental NDA for Fentora for management of breakthrough pain

FDA grants approval to Abbott for lower-strength tablet formulation of Kaletra tablet

Novel alpha3 subunit-preferring GABA-A receptor allosteric activator profiled by Neurogen